-
Study aim
-
The Effectiveness of Adding QEEG-Guided Neurofeedback to Selective serotonin reuptake inhibitors (SSRIs) in Patients with Obsessive-Compulsive Disorder (OCD)
-
Design
-
Clinical trial with control group, with parallel groups, single-blind, randomized, on 60 patients. Randomaize.com was used for randomization.
-
Settings and conduct
-
conducted at Ibn Sina Hospital, Mashhad. In this study, 60 patients with OCD are divided into two groups.
-
Participants/Inclusion and exclusion criteria
-
1- Age between 18 and 40 years.
2- Diagnosis of OCD based on DSM-5 criteria by a psychiatrist.
3-Yale-Brown Obsessive-Compulsive Scale Y-BOCS test score > 16.
5- Absence of other Axis 1 disorders,schizophrenia, bipolar disorder, depression, etc., mental retardation, substance abuse or psychiatric disorders due to medical problems that require treatment (considering the high association of obsessive-compulsive disorder with depression mild and moderate depression is allowed to enter the plan)
6- Absence of other treatment or use of cognitive therapy.
-
Intervention groups
-
In this study, 60 patients with OCD are divided into two groups, intervention and control, and by the (Y-BOCS), Beck Depression Test and Beck Anxiety Test at the beginning and end of the study, the tests Cognitive CANTAB related to obsessive-compulsive disorder and QEEG are evaluated at the beginning and end of the study and every two weeks during the study. According to the psychiatrist's diagnosis, fluoxetine 40-60 mg or the equivalent of another SSRI approved for the treatment of OCD is prescribed for the two test groups, and the intervention group receives neurofeedback based on the brain map pattern three times a week for two months.
-
Main outcome variables
-
Examining the level of obsession before and after the intervention by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) test.
changes of brain waves